Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Tamaño de envase | SKU | Disponibilidad | Precio |
|---|---|---|---|
| 25 ea | Disponible para enviar HOYdesdeToluca | MXP 2,895.00 |
Acerca de este artículo
NACRES:
NB.22
UNSPSC Code:
41123100
MXP 2,895.00
Disponible para enviar HOYDetalles
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlepore size
12,000 Da MWCO
General description
Cellulose tubing; will retain proteins with M.W. > 12,000 Da
Inflated diam. approx. 16 mm (0.64 in.); pre-cut; open ended; dry, unwashed; approx. length = 30 cm (12 in.)
1 of 1
Este artículo | |||
|---|---|---|---|
| pore size 12,000 Da MWCO | pore size 12,000 Da MWCO | pore size - | pore size - |
Still not finding the right product?
Explore all of our products under Dialysis sacks
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Contenido relacionado
Dialysis Tubing
McShane McKenna et al.
Frontiers in bioengineering and biotechnology, 8, 619252-619252 (2021-02-23)
Protein kinase B (AKT1) is hyper-activated in diverse human tumors. AKT1 is activated by phosphorylation at two key regulatory sites, Thr308 and Ser473. Active AKT1 phosphorylates many, perhaps hundreds, of downstream cellular targets in the cytosol and nucleus. AKT1 is
Atul Dev et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 80, 153386-153386 (2020-10-29)
Overexpression of polycomb protein contributes to epigenetic repression in oral squamous cell carcinoma (OSCC) ensuing in poor prognosis and aggressive phenotype. Several plant-based compounds could help prevent epigenome alteration and cancer progression, but their low bioavailability limits their therapeutic activity.
Sumit Arora et al.
Molecular pharmaceutics, 12(6), 2001-2009 (2015-04-30)
The present research aimed to develop and characterize a sustained release dry powder inhalable formulation of voriconazole (VRZ) for invasive pulmonary aspergillosis. The developed formulations were studied for their in vitro release profile, aerosol, and physicochemical properties as well as
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| D6191-25EA | 04061832336398 |